Overview
OPA recently developed and validated an AI algorithm that scans more than 35 million publications and detects topics predicted to produce transformative breakthroughs in biomedicine within the next two to twelve years (patent pending).
In the videos below, you will see representations of a topic from when research began to the realization of the breakthrough, as well as the clinical impact of the topic. Click the links below to jump to the different topics and learn more:
Therapies for HER2-low breast cancer
Emergence of PrEP behavioral research
In addition, learn about how to interpret the breakthrough on iSearch Analytic's landing page.
Note: When viewing the videos below, it is best to change the video quality using the YouTube setting icon in the bottom right corner to1080p HD for the highest quality viewing.
Therapies for HER2-low breast cancer
These papers explore the clinical and molecular features of HER2*-low breast cancer, assess the efficacy of HER2-directed therapies, and reveal new opportunities in HER2 testing and therapeutic development. They highlight the potential targetability of HER2-low cancers and evaluate the use of novel antibody-drug conjugates, such as trastuzumab deruxtecan (T-DXd), in improving overall and progression-free survival in patients with HER2-low metastatic breast cancer.
*HER2=Human Epidermal growth factor Receptor 2
Interpreting the animation
Overall, the animation shows the number of papers about HER-2 low breast cancer published from 2009-2022. The number of papers increases steadily from 2018 onward. A citation network also shows how publications become increasingly cited and clinically-focused beginning in 2018.
The blue bars represent the sum of the RCR values for the papers in each year. If the sum of RCR is equal to the number of papers, then they are being cited the same as the NIH average (1.0). If it's greater than the number of papers, then the portfolio is more influential. Learn more about RCR.
- See publications here: https://analytics.nih.gov/breakthrough/HER2_08_2023
Emergence of Car-T therapy
This research is focused on the use of chimeric antigen receptor (CAR) T-cell therapy in the treatment of various types of cancer, particularly leukemias and lymphomas. CAR T-cell therapy involves modifying a patient's own T-cells to express a receptor that targets cancer cells. The research articles discuss the efficacy, safety, and long-term outcomes of CAR T-cell therapy, as well as the management of associated toxicities such as cytokine release syndrome and neurotoxicity. The results of these studies show promising outcomes, including high response rates and durable remissions, and provide insights into the mechanisms of action and the immune responses involved in CAR T-cell therapy.
- See publications here: https://analytics.nih.gov/breakthrough/Emergence_of_CAR_T_therapy
Emergence of mRNA vaccines
mRNA vaccines represent a promising and rapidly developing approach to vaccination due to their high potency, fast development process, and potential for low-cost production. Recent technological advancements have overcome previous barriers to the in vivo delivery of mRNA, leading to encouraging results in animal models and human trials for infectious diseases and cancer. This research topic reviews the potential and future directions of mRNA vaccines in therapeutic use. The use of mRNA for other applications, such as gene therapy and protein expression, are also explored. Overall, mRNA-based therapeutics show great potential for advancing medical treatments and improving patient outcomes.
- See publications here: https://analytics.nih.gov/breakthrough/Emergence_of_mRNA_vaccines
Emergence of PrEP behavioral research
Preexposure chemoprophylaxis (PrEP) is a promising approach for preventing HIV infection by taking antiretroviral drugs before HIV exposure. Research studies have looked at the efficacy, safety, and acceptability of PrEP in various populations, including men who have sex with men, heterosexual men and women, and injecting drug users. Results have shown that PrEP can be highly effective in reducing the risk of HIV infection when used consistently. Adherence to the medication is an important factor for its effectiveness, and there is no evidence of behavioral risk compensation with PrEP use.
- See publications here: https://analytics.nih.gov/breakthrough/Emergence_of_PrEP_behavioral_research
Disclaimer: NIH tracks outputs from investigators such as publications and clinical trials. Analytics links grants to publications and individuals through both SPIRES and disambiguation. Linking does not infer an intellectual property connection between publications and awards.